Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The role of GLP-1 in healthcare continues to grow and evolve
Substances under S0 are classified as non-Specified Substances under the WADA Code, prohibited at all times in and out of competition
If a woman discovers shes pregnant while taking Wegovy, she should stop taking the drug because it may cause fetal harm, the manufacturer notes
Currently available GLP-1 receptor agonists in the UK include: Exenatide (short-acting and extended-release formulations) - licensed for type 2 diabetes Liraglutide (once-daily injection) - licensed for type 2 diabetes (Victoza) and separately for weight management (Saxenda 3mg) Dulaglutide (once-weekly injection) - licensed for type 2 diabetes, including cardiovascular risk reduction in those with established cardiovascular disease or multiple risk factors Semaglutide (once-weekly injection and oral formulation) - licensed for type 2 diabetes (Ozempic, Rybelsus) and separately for weight management (Wegovy 2.4mg) A related but distinct medication is tirzepatide (once-weekly injection), which is a dual GIP/GLP-1 receptor agonist licensed for type 2 diabetes management
US$ 28.78
US$ 25.20
US$ 21.38
US$ 24.25
US$ 23.66
US$ 27.55
US$ 25.30
